









The NCI Laboratory of Chemical Pathology has ended its 36-year project
(1961-1997) on lifetime carcinogenesis studies in cynomolgus and rhe-
sus monkeys. Our plot includes final lifetable analyses on 25 chemicals
including 17 thatwe reported earlierwith interim control data (indicated
with a "j" notecode ontheplot).'
We have relaxed some of the rules of the CPDB in order to include
these monkeyexperiments. Thefollowing methodology has beenadopted:
* Anexperimentwithfewerthan 5animals isconsidered inadequate and
is not included in the CPDB. To obtain at least 5 animals per group in
these studies, results have been combined for both sexes of cyno-
molgus and separately for both sexes of rhesus monkeys. For some
chemicals, fewer than 5 monkeys were on test even when both sexes
were combined and those are not reported; no tumors occurred in
those cases when the chemical was evaluated as not carcinogenic in
theotherspecies. Afewchemicals were studied inAfrican Green mon-
keys, but the tests usually had fewerthan 5 dosed monkeys. Because
of a viral outbreak, African Green monkey studies were discontinued.
WehaveexcludedAfrican Green studiesfromtheCPDB.
* Although experiments with surgical intervention are generally
excluded from the CPDB, in these monkeytests, laparoscopic exami-
nation of the liver was performed every 3-6 months, followed by
wedge orneedle biopsies ofobserved liver lesions.
* Afewpositive experiments are included that are shorterthan one-half
the standard 20-year life span even though such tests are generally
excluded from the CPDB. (For cycasin, 2-amino-3-methylimidazo[4,5-
f]quinoline [10], N-nitrosodipropylamine [DPN], N-nitrosodiethylamine
[DEN] in bush babies, nearlyall dosed animals had tumors inthis short
time. Some experiments on adriamycin were longerthan 10 years and
some were shorter; we have included them all forcompleteness.)The
plottedTD50 value for experiments shorter than half the life span are
surrounded byparentheses.
* Experiments on sodium arsenate and sterigmatocystin are included
eventhough monkeys were put on test as adults, at4years ofage.
* Control monkeys are from the colony at NCI, which included breed-
ers, offspring, and a small number offeral monkeys. The age of con-
trol animals ranged from neonate to greater than 25years at a given
time. Control monkeys were included only if they lived to be older
than 8 months, the age of the first tumor in any group. Concurrent,
vehicle controls were used onlyfor 10.
Some colony control monkeys were not examined histologically, and
they have been excluded from the analyses because tumors may not
have been detected at necropsy: control n = 106 cynomolgus (11 un-
examined excluded), 120 rhesus (36 unexamined excluded). We
investigated whether results would be similar ifthe unexamined con-
trols had been included in ouranalyses, and we determined thatthey
'The 25 chemicals in monkeys are 2-acetylaminofluorene, 2,7-acetylaminofluorene,
adriamycin, aflatoxin B,, sodium arsenate, azathioprine, cycasin and methyla-
zoxymethanol acetate, sodium cyclamate, cyclophosphamide, DDT, N,N-dimethy-
4-aminoazobenzene, IQ, melphalan, 3'-methyl-4-dimethylaminoazobenzene,
Nmethyl-N'-nitro-Nnitrosoguanidine, 3-methylcholanthrene, Nnitroso-N-methyl-
urea, N-nitrosodiethylamine, Nnitrosodimethylamine, Nnitrosodipropylamine, N
nitrosopiperidine, procarbazine.HCI, sodium saccharin, sterigmatocystin, and
urethane. In future we will report final results of studies on MelQx and PhIP, which
were begun at NCI and will be completed under the auspices of the Japanese
National Cancer Center Research Institute.
would be: For target sites, all results were significant (p < 0.001)
regardless of whether the unexamined were excluded or not. TD50
values calculated without unexamined animals were within a factor
of2 ofTD50values calculatedwiththem.
* The dose rate for a group is calculated as the mean ofthe dose-rate
of individual monkeys. To obtain the daily dose rate for each mon-
key, the cumulative dose in mg/kg reported by NCI, was divided by
the number of days of its life. Dosing schedules ranged across
chemicals from once every 4 weeks to 5 times per week; for most
experiments the chemicals were administered in a vitamin sandwich
5times perweek.
* TD50 values are estimated using lifetable data and are reported for
every site at which a tumor occurred, benign or malignant, in dosed
animals.
* In experiments with multiple target sites, a composite TD50 value is
reported on the plot for all animals with tumors at any of the target
sites("MXB,MXB" onthe plot, aswith NCI/NTPbioassays in rodents).
See Appendix 6, Notecodes and Definitions, under "W" and `w for
details aboutplotted results on monkeys.

























































used for two compounds in monkeys: 1) procarbazine.HCI: a
variety of combinations of diet, subcutaneous, intraperitoneal,
and intravenous injection; 2) aflatoxin B,: a combination of diet
and intraperitoneal injection
orl fortamoxifen citrate, gavage for 3 months, followed by diet
wat water

































































































































more than one site, combined by NCI/NTP


































all tumor bearing animals, NCI/NTP













































intrahepatic bile ducttumor, benign
intrahepatic bile duct tumor































































lmt lymphoma malignant, thymic origin







mix morethan onetumortype; tumortypesspecified inpublished paper
mly malignant lymphoma





MXA morethan one tumortype, combined by NCI/NTP
MXB more than one tumortype, combined by Berkeley








pbb pheochromocytoma benign, bilateral
pda pars distalis adenoma




pmb pheochromocytoma malignant, bilateral
pob pheochromocytoma, benign
ppa papillary adenoma












sxb sex-cord stromal tumor, benign, bilateral











































































tsc transitional epithelium, squamous-cell carcinoma
tsp transitional epithelium, squamous-cell papilloma
tum tumor or more than one tumortype; tumor types not specified in
paper
Appendix 6. Notecodes and Definitions
Code Definition
a The exposure time reported on the plot is an average of the dif-
ferent exposure times of the individual dose groups in the
experiment. For NCI/NTP, both exposure and experiment times
have been averaged because of differential survival among the
dose groups. (In the TD50 calculation forthe NCI/NTP bioassays,
full lifetable data have been used.)
C Quantitative data is reported in the paper on cell division in
dosed and control animals (e.g., labeling index). The "C" note-
code does not indicate whether there was an association
between cell division and tumorigenesis.
D Dietary restriction
e For the general literature we have used an effective number of
animals in a group whenever possible. This effective number is
either: 1) the number of animals alive atthe time of appearance
of the first tumor, or if that is not reported, then 2) the number
ofanimals examined.
g Some or all of the animals were used as breeders during the
course ofthe experiment.
Control and dosed animals received isocaloric diets.
j The data for this test have been previously published in the
CPDB. The experimental results have been revised either
because of a later publication by the same authors or because
of a personal communication. In the CPDB, we give the same
reference number tothe experiment in all plot publications.
k For interim and serial sacrifice experiments, we have reported,
as a separate experiment with a "k" notecode, each sacrifice
time that otherwise met the inclusion rules of the database.
Wherever possible, we have included unscheduled deaths with
the terminal sacrifice data, and when this has been done, there
is no "k" notecode fortheterminal sacrifice experiment.
m The calculated dose level for a group is an average of either (1)
different doses administered to individual animals, or (2) the
range ofdoses administered.
r Restricted site analysis; the authors either examined or chose to
report data foronly a fewselected tissues.
s Authors noted that survival was decreased because of toxicity,
disease, oraccidental death.
v Variable or irregular dosing schedules have been used, e.g.,
dose level changed during the experiment.
w For nonhuman primates, denominators for tumor incidence on the
plotrepresentthe numberalive atthe age ofthefirsttumorofthat
type; since that age varies fordifferent tumortypes, denominators
onthe plotforcontrol and dosed animals canvarywidelyfrom one
site to another within an experiment. Only a few chemicals were
tested at morethan one dose level; we usethesymbol "-/-" to
indicate that for one of the dose groups all animals were dead
before the occurrence oftumors ofthattype in another group. The
maximum numberofanimals used in anyTD50for an experiment is
indicated bythedenominatorofthe tumorincidencefor "all tumor-
bearing animals" ("tba" on the plot) and represents the number
alive atthefirsttumor in anygroup.
W Tumors in control monkeys that lived longer than the last dosed
animal in the experiment are deleted from the analysis. See
Appendix 1 for details on monkey experiments.




/ significant departure from linearity, upward curvature
\ significant departure from linearity, downward curvature
Z significant departure from linearity, more than three dose
groups including controls
blank either no dose-related effect, or no curve shape could be deter-





<+ 100% of dosed animals had thetumoron this line ofthe plot
> Forall TD50s in the experiment p> 0.10
99% confidence limits for lifetableTD50
99% confidence limits for summaryTD50
() Length of the experiment is less than 1/2 the standard life span
or exposure is less than 1/4 the standard life span. The cases
are primarily a) of borderline lengths, b) stop-exposure tests of
NTP in addition to a 2-year bioassay, c) or NCI monkey studies
forwhich length criteria ofthe CPDB have been relaxed.
Appendix 8. Author's Opinion
Code Author'sOpinionforEachSite
c NTP evaluation is clear evidence of carcinogenic activity, i.e.,
"studies that are interpreted as showing a dose-related (i)
increase of malignant neoplasms, (ii) increase of a combination
of malignant and benign neoplasms, or (iii) marked increase of
benign neoplasms if there is an indication from this or other
studies ofthe ability of such tumors to progress to malignancy."
e NTP evaluation is equivocal evidence of carcinogenic activity,
i.e. "studiesthat are interpreted as showing a marginal increase
of neoplasms that may bechemicallyrelated."
p NTP evaluation is some evidence of carcinogenic activity, i.e.
"studies that are interpreted as showing a chemically related
increased incidence of neoplasms (malignant, benign, or com-
bined) in which the strength of the response is less than that
required forclear evidence."
+ Author in general literature evaluated site as positive.
- NTP evaluation is no evidence of carcinogenic activity, i.e.
"studies that are interpreted as showing no chemically related
increases in malignant or benign neoplasms." In the general lit-
erature author evaluated the site as negative.
blank ForNTPandgeneral literature: a siteforwhich noopinion isstated.
Appendix 9. Berkeley Codes
Code DefinitionsofBerkeleyCodesforNCI/NTP
C The TD50 includes all animals with a tumor at any site with a
"c" opinion. The mix was created for the CPDB, and MXB
appears on the left side ofthe plot.
S The TD50 has been included in the plot because the sites were
statistically significant in the tables of analyses of primary
tumors and the TD50 was significant at the p < 0.05 level; how-
ever, the NCI/NTP report did not evaluate the site as evidence
ofcarcinogenicity.




ajim American Journal of Industrial Medicine





cebp Cancer Epidemiology, Biomarkers & Prevention
clet Cancer letters
cmde Carcinogenic and Mutagenic Effects of Diesel Engine Exhaust(N
Ishinishi, A Koizumi, RO McClellan, W Stober, eds). New
York:Elsevier Science, 1986.
dact Drug and Chemical Toxicology
eaes Ecotoxicology and Environmental Safety
ejca European Journal of Cancer and Clinical Oncology (formerly
European Journal ofCancer, until 1982)
enhp Environmental Health Perspectives
extp Experimental andToxicologic Pathology
faat Fundamental and Applied Toxicology (journal name changed to
Toxicological Sciences in December 1997)
fctx Food and Chemical Toxicology (formerly Food and Cosmetics
Toxicology, until 1982)
gann Japanese Journal of Cancer Research (formerly Gann until 1984)
ijcn International Journal of Cancer (formerly International Union
Against Cancer until 1964)
indh Industrial Health
jact Journal oftheAmerican College ofToxicology
japt Journal ofApplied Toxicology
jnci Journal of the National Cancer Institute (U.S. National Cancer
Institute Journal)
jtxe Journal ofToxicology and Environmental Health
jtxs Journal ofToxicological Sciences
onco Oncology
oncr Oncology Reports
ossc Organ and Species Specificity in Chemical Carcinogenesis




pseb Proceedings of the Society for Experimental Biology and
Medicine (NewYork)
rtxp RegulatoryToxicology and Pharmacology
stnd Safety Testing of New Drugs: Laboratory Predictions and Clinical
Performance (DR Laurence, AEM McLean, M Weatherall, eds),
Orlando, FL:Academic Press, 1984.
tcam Teratogenesis, Carcinogenesis, and Mutagenesis
txap Toxicologyand Applied Pharmacology
txcy Toxicology
txih Toxicology and Industrial Health
txit Toxicology Letters
txpy Toxicologic Pathology
Appendix 11. Chemical Names and Synonyms
in this Plot


















76180-96-6 2-AMINO-3-METHYLIMIDAZO[4,5-f] QUINOLINE(see 10)
60-32-2 6-AMINOCAPROICACID













25013-16-5 BHA(see BUTYLATED HYDROXYANISOLE)
























alpha-(1-METHYLETHYL) BENZENE ACETATE (see FEN-
VALERATE)
mixture CYCASIN AND METHYLAZOXYMETHANOL ACETATE
(CAS NUMBER 592-62-1 and 14901-08-7)













CAS Number Chemical Name
139-05-9 CYCLAMATE, SODIUM
50-18-0 CYCLOPHOSPHAMIDE
50-18-0 CYTOXAN (see CYCLOPHOSPHAMIDE)
60-11-7 DAB (see N,N-DIMETHYL-4-AMINOAZOBENZENE)
79-43-6 DCA(see DICHLOROACETIC ACID)
50-29-3 DDT
117-81-7 DEHP (see DI(2-ETHYLHEXYL) PHTHALATE)
53-43-0 DEHYDROEPIANDROSTERONE
141-05-9 DEM (see DIETHYLMALEATE)
55-18-5 DEN (see N-NITROSODIETHYLAMINE)
56-53-1 DES (see DIETHYLSTILBESTROL)
50-02-2 DEXAMETHAZONE








6]1INDOLE-1-ACETIC ACID (see ETODOLAC)
141-05-9 DIETHYLMALEATE
55-18-5 DIETHYLNITROSAMINE (see N-NITROSODIETHYLAMINE)
56-53-1 DIETHYLSTILBESTROL
70052-12-9 2-(DIFLUOROMETHYL)-DL-ORNITHINE
120-80-9 1,2-DIHYDROXYBENZENE (see CATECHOL)
60-11-7 N,N-DIMETHYL-4-AMINOAZOBENZENE
68-12-2 DIMETHYLFORMAMIDE





121-14-2 2,4-DINITROTOLUENE (CONTAINING 1.0-1.5% 2,6-
DINITROTOLUENE)
57-41-0 5,5-DIPHENYLHYDANTOIN
621-64-7 DIPROPYLNITROSAMINE (see N-NITROSODIPRO-
PYLAMINE)





50-18-0 ENDOXAN (see CYCLOPHOSPHAMIDE)
989-51-5 (-)-EPIGALLOCATECHIN GALLATE (85% (-)-EPIGALLO-
















53-96-3 FLUORENYLACETAMIDE (see 2-ACETYLAMINO-
FLUORENE)
CAS Number Chemical Name





59721-29-8 FOY 305 (see CAMOSTAT MESYLATE)
3296-90-0 FR-1138 (see 2,2-BIS(BROMOMETHYL)-1,3-PROPANE-
DIOL, TECHNICAL GRADE)
75-09-2 FREON 30 (see METHYLENE CHLORIDE)
149-91-7 GALLIC ACID
118-74-1 HCB(see HEXACHLOROBENZENE)












123482-23-5 LY277359 MALEATE (see ZATOSETRON MALEATE)
mixture MAM ACETATE AND CYCASIN (see CYCASIN AND
METHYLAZOXYMETHANOL ACETATE)





2425-06-1 MERPAFOL (see CAPTAFOL)
934-00-9 3-METHOXYCATECHOL
150-76-5 4-METHOXYPHENOL
78-79-5 2-METHYL-1,3-BUTADIENE (see ISOPRENE)
1634-04-4 METHYLtert-BUTYL ETHER
75-05-8 METHYL CYANIDE(see ACETONITRILE)
55-80-1 3'-METHYL-4-DIMETHYLAMINOAZOBENZENE
70-25-7 N-METHYL-N'-NITRO-N-NITROSOGUANIDINE
684-93-5 N-METHYL-N-NITROSOUREA (see N-NITROSO-N-
METHYLUREA)
75-65-0 2-METHYL-2-PROPANOL(see tert-BUTYLALCOHOL)
mixture METHYLAZOXYMETHANOL ACETATE AND CYCASIN
MIXTURE (see CYCASIN AND METHYLAZOXY-
METHANOL ACETATE)
452-86-8 4-METHYLCATECHOL






64091-91-4 4-(METHYLNITROSAMINO)-1 -(3-PYRIDYL)-1 -
(BUTANONE)
298-59-9 METHYLPHENIDATE.HCI
70-25-7 MNNG (see N-METHYL-N'-NITRO-N-NITROSOGUANI-
DINE)
684-93-5 MNU (see N-NITROSO-N-METHYLUREA)
79-11-8 MONOCHLOROACETIC ACID
108-88-3 MONOMETHYL BENZENE(seeTOLUENE)
76-57-3 MORPHINE MONOMETHYL ETHER(see CODEINE)
1634-04-4 MTBE(see METHYLtert-BUTYL ETHER)
3771-19-5 NAFENOPIN




10101-97-0 NICKEL(II) SULFATE HEXAHYDRATE












684-93-5 NITROSOMETHYLUREA (see N-NITROSO-N-
METHYLUREA)
100-75-4 N-NITROSOPIPERIDINE
64091-91-4 NNK (see 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-
(BUTANONE))
29082-74-4 OCTACHLOROSTYRENE
117-81-7 DI-sec-OCTYL PHTHALATE (see DI(2-ETHYlHEXYl)-
PHTHALATE)
64224-21-1 OLTIPRAZ






























148-82-3 L-SARCOLYSIN (see MELPHALAN)
SDZ200-110
7647-14-5 SODIUM CHLORIDE
28302-36-5 SODIUM COPPER CHLOROPHYLLIN
139-05-9 SODIUM CYCLAMATE(seeCYCLAMATE, SODIUM)
10588-01-9 SODIUM DICHROMATE
7632-00-0 SODIUM NITRITE(see NITRITE, SODIUM)
10048-13-2 STERIGMATOCYSTIN
54965-24-1 TAMOXIFEN CITRATE
CAS Number Chemical Name
1401-55-4 TANNIC ACIDS, PHARMACEUTICAL GRADE (85.69%
TANNICACIDS, 8.84% GALLICACIDS)
76-03-9 TCA(seeTRICHLOROACETICACID)




















127-47-9 VITAMIN A,ACETATE(see RETINOLACETATE)
50-81-7 VITAMIN C(see L-ASCORBICACID)
115436-74-3 WIN 54177-4(see IPAZILIDE FUMARATE)
50892-23-4 WY14643 (see [4-CHLORO-6-(2,3-XYLIDINO)-2-
PYRIMIDINYLTHIO]ACETICACID)
mixture XYLENE MIXTURE (50.31% m-XYLENE, 26.9% o-
XYLENE, 22.24% p-XYLENE) (CAS NUMBER 108-38-3,
95-47-6, and 106-42-3)
60-11-7 BUTTER YELLOW (see N,N-DIMETHYL-4-AMINOAZO-
BENZENE)
123482-23-5 ZATOSETRON MALEATE
CAS NUMBER =Chemical Abstracts Service registry number
Appendix 12. Chemical Names in this Plot
Listed byCAS Number
CASNumber Chemical Name
mixture XYLENE MIXTURE(50.31% m-XYLENE, 26.9% o-XYLENE,
22.24% p-XYLENE) (CAS NUMBER 108-38-3, 95-47-6,
and 106-42-3)
mixture CYCASIN AND METHYLAZOXYMETHANOL ACETATE


















57-30-7 PHENOBARBITAL, SODIUM (phenobarbitone, sodium)














































2,4-DINITROTOLUENE (CONTAINING 1.0-1.5% 2,6-
DINITROTOLUENE)































989-51-5 (-)-EPIGALLOCATECHIN GALLATE (85% (-)-EPIGALLO-
CATECHIN GALLATE, 10% (-)-EPIGALLOCATECHIN, 5%
(-)-EPICATECHIN GALLATE)
1162-65-8 AFLATOXIN Bi
1401-55-4 TANNIC ACIDS, PHARMACEUTICAL GRADE (85.69%
TANNIC ACIDS, 8.84% GALLICACIDS)
1582-09-8 TRIFLURALIN, TECHNICAL GRADE



























25013-16-5 BUTYLATED HYDROXYANISOLE (BHA, 2(3)-tert-butyl-4-
hydroxyanisole)
26471-62-5 TOLUENE DIISOCYANATE, COMMERCIAL GRADE (2,4
(80%)-AND2,6(20%)-)
27774-13-6 VANADYLSULFATE








































































CAS Number Chemical Name



















115436-74-3 IPAZILIDE FUMARATE (WIN 54177-4)











CAS NUMBER =Chemical Abstracts Service registry number.
Appendix 13. Bibliography: National
Toxicology Program Technical Reports
Technical Publication




tert-Butyl alcohol TR436 1995
Codeine TR455 1996
Isobutyl nitrite TR448 1996
Isoprenea TX31 1995
Methylphenidate.HCI TR439 1995
Nickel sulfate hexahydrate TR454 1996
Phenolphthalein TR465 1996
1-trans-69-Tetrahydrocannabinol TR446 1996
aThe isoprene test in mice was reported in the NTP Toxicity Report
series (indicated by "TX"), rather than the Techincal Report series (indi-
cated by "TR"). Additional information for our analyses was reported in
Melnick et al. (91)which is referenced in Appendix 14.
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